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Abstract 
Background: DNA methylation has emerged as an important regulator of development and disease, necessitating 
the design of more efficient and cost-effective methods for detecting and quantifying this epigenetic modification. 
Next-generation sequencing (NGS) techniques offer single base resolution of CpG methylation levels with high statis-
tical significance, but are also high cost if performed genome-wide. Here, we describe a simplified targeted bisulfite 
sequencing approach in which DNA sequencing libraries are prepared following sodium bisulfite conversion and two 
rounds of PCR for target enrichment and sample barcoding, termed BisPCR2.
Results: We have applied the BisPCR2 technique to validate differential methylation at several type 2 diabetes risk loci 
identified in genome-wide studies of human islets. We confirmed some previous findings while not others, in addi-
tion to identifying novel differentially methylated CpGs at these genes of interest, due to the much higher depth of 
sequencing coverage in BisPCR2 compared to prior array-based approaches.
Conclusion: This study presents a robust, efficient, and cost-effective technique for targeted bisulfite NGS, and illus-
trates its utility by reanalysis of prior findings from genome-wide studies.
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Background
DNA methylation refers to the addition of a methyl 
group to the 5-carbon position of cytosine residues, and 
in mammalian genomes occurs most commonly in the 
context of CpG dinucleotides. As an epigenetic mark, this 
chemical modification does not alter the DNA sequence, 
but rather regulates transcriptional programs to direct 
processes such as cellular differentiation, genomic 
imprinting, and X-chromosome inactivation, while pro-
moting genomic stability [1–4]. The majority of CpGs 
throughout the mammalian genome are fully methylated, 
while the remainder exists in an unmethylated or lowly 
methylated state, corresponding to active regulatory ele-
ments such as promoters and enhancers [4–8]. Aberrant 
DNA methylation has been implicated in an increasing 
number of morbidities, particularly cancer and aging-
associated diseases such as type 2 diabetes, neurological 
disorders, and cardiovascular disease [9–11]. Many of the 
studies linking DNA methylation to disease have been 
prompted by the observation that only a small fraction 
of the inherited risk of these complex disorders can be 
explained by genetic variation, as determined by genome-
wide association studies (GWAS) [12, 13]. DNA methyla-
tion, along with other epigenetic alterations, may provide 
the link between environmental factors or intrauterine 
exposure and complex disorders.
A key challenge in the epigenetics field has been achiev-
ing high-resolution genome-wide detection of these 
modifications in sufficient sample sizes to make claims 
about disease association. In mapping DNA methyla-
tion, the most advanced technologies include array-based 
techniques such as the Infinium HumanMethylation450 
BeadChip, which assays 450,000 individual CpGs among 
99% of RefSeq genes, and whole genome shotgun bisulfite 
sequencing (WGBS), which maps cytosine methyla-
tion across the entire genome at single base resolution, 
covering approximately 30 million CpGs. While array-
based approaches are more cost-effective and higher 
throughput, the restrictive sampling of CpGs provides an 
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incomplete landscape of the methylome [14]. However, 
WGBS experiments are extremely resource-intensive, 
because exhaustive sequencing is required to achieve suf-
ficient coverage to accurately determine the percentage 
of methylation at all CpGs. Therefore, it is only practical 
to conduct WGBS on a limited number of samples, and 
coverage is usually in the range of 5–15X per CpG, limit-
ing statistical significance of findings. In both instances, 
novel findings need to be validated in larger populations 
through targeted methylation analyses. Thus, there is an 
increasing need for targeted sequencing techniques that 
are high-throughput, cost-effective, and provide single 
base resolution.
Next-generation sequencing (NGS) strategies have 
been developed as an alternative to fluorescence-based 
pyrosequencing, which is limited by the number of sam-
ples that can be processed, and the fact that its short read 
lengths cover only a few CpGs at a time. These protocols 
entail PCR amplification of target regions from bisulfite-
converted genomic DNA, followed by DNA sequencing 
library preparation using techniques such as standard 
Illumina protocols or transposase-based Nextera XT 
technology [15, 16]. While providing precise and accurate 
DNA methylation data with high statistical significance, 
DNA sequencing library preparation is quite expensive 
and cumbersome when evaluating large numbers of sam-
ples or target regions.
Therefore, we have developed a novel approach for 
constructing targeted bisulfite NGS libraries that are 
prepared by bisulfite conversion of genomic DNA fol-
lowed by two rounds of PCR, termed BisPCR2, elimi-
nating the need for traditional DNA library preparation 
procedures (Fig.  1). In the BisPCR2 method, the entire 
library preparation process has been reduced to a single 
50-min PCR reaction. We have validated the usefulness 
of this method in the context of type 2 diabetes, first con-
firming reported differences in DNA methylation at the 
imprinted MEG3 locus, and by validation of previous 
genome-wide findings of CpG risk loci identified in type 
2 diabetic human islets [17, 18].
Results
The BisPCR2 method for targeted bisulfite sequencing
In order to simplify targeted bisulfite NGS, we devel-
oped a PCR-based method for library preparation, 
termed BisPCR2 (Fig. 1). The first step in this procedure 
is sodium bisulfite treatment of genomic DNA (gDNA), 
which deaminates unmethylated cytosines to uracils, 
while methylated cytosines are protected. In subsequent 
PCR amplification reactions, uracils are amplified and 
ultimately sequenced as thymine residues. The goal of 
the first PCR (PCR#1) is target enrichment to amplify 
regions of interest from bisulfite-converted gDNA. The 
target enrichment primers have overhangs with partial 
adapter sequences that are subsequently used to amplify 
barcoded libraries in the second round of PCR (PCR#2). 
Target enrichment PCR products (PCR#1) for each sam-
ple are pooled prior to PCR#2 to simultaneously add the 
same multiplexing indices to all amplicons of interest. A 
detailed diagram of BisPCR2 primer design is provided in 
Additional file 1: Figure S1. Following sample barcoding, 
all PCR#2 reactions are purified and pooled for sequenc-
ing on the Illumina Miseq with 150 base pair paired-end 
reads. We found that purification of final libraries with 
AMPure XP beads efficiently removed primer dimers in 
comparison to column based PCR purification (data not 
shown). To prove that BisPCR2 is comparable to tradi-
tional targeted bisulfite NGS approaches, we measured 
DNA methylation at the H19 locus in mouse genomic 
DNA using both methods and found nearly identical 
results (Additional file 2: Figure S2).
BisPCR2 library construction and sequencing
In this study, we selected five target loci for evaluation, 
as described below, and compared their DNA methyla-
tion profile in five non-diabetic and five type 2 diabetic 
human islet samples. Pancreatic islet donor information 
is provided in Table 1. Thus, for each of these ten biologi-
cal samples, five PCR#1 amplicons were pooled, purified, 
and then used as template for the PCR#2 barcoding reac-
tion. Target regions ranged in size from 171 to 298 bps 
(Table 2), and PCR#2 conditions were optimized to pre-
vent amplification bias, particularly of smaller fragments, 
with the goal of balancing each library with roughly 
equivalent amounts of each amplicon (Fig. 2a, b).  
The MiSeq sequencing run produced 14.15 million 
reads, with 12.75 million passing filter. The sample was 
spiked with 10% PhiX control, and 8.5% of total reads 
were aligned to the PhiX genome. Approximately 85% 
of remaining reads, or 10 million, were aligned to the 
human genome. Therefore, the expected number of reads 
per amplicon per sample was approximately 200,000 
reads. The percentage of reads allocated to each of the ten 
samples ranged from 7.01 to 12.45% (Fig. 2c). The slight 
deviation from the expected 10% per sample is likely due 
to small pipetting errors when preparing the sequencing 
pool. Across all samples, the average read number per 
locus was 206,411, ranging from 78,000 to 358,000 reads 
(Fig. 2c). The range in sequencing depth is likely due to 
imprecise pooling of PCR#1 products. The amount of 
each PCR#1 product pooled was based on relative band 
intensity of one representative sample, non-diabetic 1 
(ND1), run on a 1.5% agarose gel, and does not account 
for sample to sample variability, which we anticipated to 
be low. This approximation is suitable for many applica-
tions of the BisPCR2 method, although samples could be 
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Fig. 1 Schema of BisPCR2 method for targeted bisulfite sequencing. DNA sequencing libraries are prepared by bisulfite conversion of genomic 
DNA followed by two rounds of PCR for target enrichment (PCR#1) and subsequent sample barcoding (PCR#2). Partial adapter overhangs are added 
to target enrichment primers to permit simplified library preparation by PCR. PCR#1 amplicons are pooled prior to the PCR#2 reaction for each 
biological sample. Due to the presence of the unique barcodes, all PCR#2 amplicons can be pooled for a single next-generation sequencing run.
Page 4 of 9Bernstein et al. Epigenetics & Chromatin  (2015) 8:27 
assessed for pooling independently if so desired. Never-
theless, even the minimal read depth of 78,000 allows for 
exceedingly precise determination of methylation levels.
Validation of type 2 diabetes differentially methylated loci
We tested our BisPCR2 targeted bisulfite sequencing 
approach by measuring DNA methylation of the pro-
moter region of MEG3 in human pancreatic islets. MEG3 
is a complex imprinted locus that produces 54 microR-
NAs, the MEG3 lncRNA, and multiple additional small 
RNA species. MEG3 was shown to be down-regulated 
with corresponding promoter hypermethylation in type 2 
diabetic (T2D) human islets [17]. As an imprinted locus, 
the MEG3 promoter is expected to be approximately 50% 
methylated in normal human islets, and thus it is an ideal 
target for validating the BisPCR2 strategy.
Target enrichment primers were designed to amplify 
a 298 base pair region within the MEG3 promoter at 
position −188 to −493  relative to the transcription 
start site. This amplicon covered 19 CpGs, and the aver-
age CpG methylation across the region was significantly 
increased from 43% in non-diabetic to 61% in type 2 dia-
betic human islets (p < 0.0001), confirming the report by 
Kameswaran and colleagues. Of the 19 CpGs covered, 
14 had significantly increased CpG methylation in type 
2 diabetics (p  <  0.05) (Fig.  3a). To further corroborate 
our findings, using primers directed to the same target 
region, we technically validated our results with pyrose-
quencing. Although the same target region was analyzed, 
the fluorescence-based pyrosequencing reaction covered 
only 2 of the 19 CpGs within the amplicon, #15 and #16. 
These 2 CpGs showed comparable levels of CpG meth-
ylation in the non-diabetic and type 2 diabetic samples 
as the BisPCR2 method (Fig. 3b). Thus, we were able to 
technically validate our results with pyrosequencing, 
and analyze ten times as many CpGs with the BisPCR2 
method.
We next sought to employ the BisPCR2 strategy to vali-
date published differentially methylated loci in islets from 
type 2 diabetics [18]. We selected four genes, INS, IRS1, 
CDKN1A, and PDE7B, for validation. These loci were 
among those determined by Dayeh and colleagues to be 
differentially methylated in type 2 diabetic human islets 
in a genome-wide screen conducted with the Infinium 
HumanMethylation450 BeadChip array [18]. The insulin 
gene has also been described as differentially methylated 
in type 2 diabetic human islets through a candidate gene 
approach [19]. We designed PCR#1 primers targeting the 
region −112 to −336 base pairs upstream of the insu-
lin transcription start site capturing four CpGs, three of 
which were previously reported to have increased DNA 
methylation in type 2 diabetic human islets [18]. We 
found all four CpGs measured had significantly increased 
DNA methylation (p  <  0.05) with an average of 24% in 
non-diabetic compared to to 46% in type 2 diabetic sam-
ples (p  <  0.0005) (Fig.  4a). This includes one CpG from 
the Infinium array that was not previously identified as 
differentially methylated, INS CpG #4 (cg24338752).
Individual CpGs within the other three loci had previ-
ously been re-analyzed by pyrosequencing, and we modi-
fied these pyrosequencing primers with PCR#1 adapter 
overhangs to adapt these amplicons to the BisPCR2 
technology [18]. By using the BisPCR2 method with the 
same amplicons we were able to directly quantify DNA 
methylation at all CpGs within the target region. At the 
IRS1 locus, we measured a comparable decrease of 10% 
CpG methylation in type 2 diabetic human islets, from 
47 to 37%, at IRS1 CpG #1 (cg04751089), as had been 
reported previously (Fig.  4b) [18]. In this amplicon we 
also determined DNA methylation at two adjacent CpGs 
that were not included in the Infinium array, and while 
the changes trended in a similar direction, there was no 
significant difference between non-diabetic and type 2 
diabetic samples. At the CDKN1A locus, we did not find 
a significant difference in DNA methylation at the CpG 
previously analyzed by pyrosequencing, CDKN1A CpG 
Table 1 Human pancreatic islet donor information
Donor Gender Age (years) BMI (kg/m2)
Non-diabetic 1 M 50 29.1
Non-diabetic 2 F 59 28.3
Non-diabetic 3 M 49 31.3
Non-diabetic 4 M 60 22.5
Non-diabetic 5 M 51 38.9
Type 2 diabetic 1 M 58 29.3
Type 2 diabetic 2 M 43 37
Type 2 diabetic 3 F 40 33.9
Type 2 diabetic 4 F 57 48.4
Type 2 diabetic 5 M 47 NA
Table 2 Description of  PCR products assessed for  DNA 
methylation analysis
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#1 (cg21091547), but did observe a significant decrease 
of 10% at two adjacent CpGs captured in this amplicon 
(Fig. 4c). CDKN1A CpG #3 (cg24425727) was also iden-
tified as differentially methylated to a similar extent in 
the genome-wide study by Dayeh and colleagues, while 
CDKN1A CpG #2 (cg11920449) was not previously iden-
tified as differentially methylated [18]. Lastly, we did not 
observe a change in DNA methylation at any of the three 
CpGs assayed at the PDE7B locus (Fig. 4d). Thus, in our 
validation study using BisPCR2, we were able to confirm 
some previous genome-wide findings and not others, 
while making novel observations about additional nearby 
CpGs not covered in prior assays.
Discussion
We were prompted to develop the BisPCR2 method by 
our need for a high-throughput, cost-effective method 
for interrogating multiple CpGs at base resolution 
within multiple target loci of interest. Fluorescence-
based approaches to targeted bisulfite sequencing are 
limited by the number of CpGs that can be measured at 
one time, the inability to multiplex, and the reliance of 
measurements on a secondary enzymatic reaction. Next-
generation sequencing techniques for targeted bisulfite 
sequencing employ the same strategy of bisulfite conver-
sion and amplification of target loci, but result in a far 
more robust output by directly measuring base content 
Fig. 2 BisPCR2 DNA sequencing libraries. a Bioanalyzer gel visualizing the five amplicon fragments of a representative sample, ND1, following 
PCR#2. b Bioanalyzer electropherogram quantifying the amount of each fragment in ND1, illustrating the roughly equivalent amounts of all five 
amplicons. c Average reads per amplicon for each sample. ND non-diabetic, T2D type 2 diabetic.
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of each CpG within an amplicon. Further, the ability to 
multiplex means that a single sequencing reaction can 
yield information about multiple target loci for multiple 
biological samples. One impediment of NGS approaches 
is the additional step of DNA sequencing library prepara-
tion following target enrichment, which can be expensive 
and time consuming. We have circumvented this chal-
lenge by modifying the target enrichment PCR prim-
ers with overhangs such that DNA sequencing libraries 
can be directly amplified from target enrichment ampli-
cons. This modification dramatically decreases time and 
expense required for this NGS approach.
We technically validated the BisPCR2 method at the 
imprinted MEG3 locus, which was previously shown to 
be hypermethylated in type 2 diabetic human islets [17]. 
We confirmed previous findings by both BisPCR2 and 
pyrosequencing and demonstrated that BisPCR2 meas-
ures DNA methylation at 19 CpGs, while pyrosequenc-
ing measures only two despite identical target sequence 
inputs. Further, our validation study of type 2 diabetes 
CpG risk loci highlights several important considerations 
about implementing targeted DNA methylation analysis, 
particularly as a diagnostic marker. In some instances, 
such as IRS1, our results were nearly identical to those 
reported by Dayeh and colleagues [18]. We found similar 
levels of DNA methylation in normal and type 2 diabetic 
human islets at IRS CpG #1 (cg04751089) and found no 
significant changes at two adjacent CpGs that were not 
probed for on the Infinium HumanMethylation450 Bead-
Chip. However, in contrast to genome-wide findings, we 
did not observe a change in DNA methylation at PDE7B 
CpG #2 (cg27306443), or at adjacent CpGs. While this 
discrepancy may be due to our limited sample size, it 
stresses the point that CpG methylation at this locus is 
not a sufficient diagnostic indicator of type 2 diabetes. 
Our findings at the CDKN1A locus highlight a third 
point, as we did not measure a change in CpG methyla-
tion at the reported cg21091547 (CDKN1A CpG #1), but 
did find a significant decrease in methylation at two adja-
cent CpGs, one of which was also identified by Dayeh 
and colleagues [18]. These results again stress the dan-
ger of relying on a single CpG for reporting methylation 
changes, and also emphasize the value in incorporating 
multiple CpGs for the understanding of how DNA meth-
ylation is implicated in disease risk.
While we have demonstrated the utility of BisPCR2 in 
validating findings from genome-wide DNA methylation 
analyses, this technology is also suitable for other appli-
cations including candidate gene approaches and clinical 
diagnostic assays. In candidate gene approaches, where 
genome-wide analyses may not be possible, many regions 
can be surveyed simultaneously by pooling multiple 
PCR#1 products across larger sample sizes than would 
be feasible for fluorescence-based assays. Clinical appli-
cations can benefit as well by reducing the costs of NGS 
approaches while collecting high-resolution data about 
neighboring CpGs, the value of which was discussed 
earlier. It should also be noted that our particular study 
does not take full advantage of the sequencing capacity 
of the MiSeq, as 200,000 reads per amplicon is orders of 
Fig. 3 BisPCR2 DNA methylation analysis confirms increased CpG methylation in type 2 diabetic human islets at the MEG3 locus. a Average percent 
CpG methylation at the MEG3 locus for five non-diabetic and five type 2 diabetic human islet samples measured by BisPCR2. p values calculated 
by a two-tailed t test. *p < 0.05. Error bars indicate SEM. b Quantification of average percent CpG methylation by pyrosequencing using the same 
samples and same MEG3 PCR primer sequences as in a. Only 2 of 19 CpGs are covered in the pyrosequencing assay. Data displayed as in a.
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magnitude beyond what would be sufficient to draw sta-
tistically significant conclusions. Considering a sequenc-
ing threshold of 1,000 reads per amplicon, the capacity of 
the number of amplicons and samples that can be ana-
lyzed in one run could be increased by two hundred-fold. 
This excess capacity could be distributed to additional 
samples or additional target loci, or a combination of 
both. We provide 48 single index barcoding primers 
based on widely used Illumina sequencing technology, 
which would accommodate 250 target loci per sample. 
Further, the barcoding primers could easily be modified 
with dual indices to increase multiplexing capacity, which 
may be of particular utility in a clinical assay.
Conclusion
BisPCR2 is an efficient, cost-effective, and robust high-
throughput technique for assessing DNA methylation 
at targeted loci of interest. Replacing DNA sequencing 
library preparation with a single round of PCR represents 
a significant improvement over other targeted bisulfite 
NGS approaches by reducing time and cost. This method 
is easily adaptable to different experimental setups to 
address a wide variety of biological questions relevant to 
DNA methylation.
Methods
Traditional targeted bisulfite NGS library preparation 
(BisPCRSeq)
100 ng of mouse genomic DNA, isolated from the intes-
tinal epithelium of 3  month old C57BL/6  J-ApcMin/J 
mice (Jackson Laboratories), was bisulfite converted 
using the Epitect bisulfite kit (Qiagen). Template DNA 
was amplified using KAPA HIFI Uracel  +  (KAPA) 
with primers directed to the H19 locus (Forward: 
Fig. 4 Validation of CpG loci differentially methylated in type 2 diabetic pancreatic islets by BisPCR2. Average percent CpG methylation in 5 non-
diabetic and 5 type 2 diabetic human islet samples at loci previously shown to be differentially methylated in type 2 diabetic human islets, includ-
ing a INS, b IRS1, c CDKN1A, and d PDE7B. Black arrows indicate CpGs analyzed previously by pyrosequencing by Dayeh and colleagues [18]. p value 
calculated by two-tailed t tests. *p < 0.05. Error bars indicate SEM.
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5′-ATTAGTTAGTGTGGTTTATTATAGGAAG-3′ and 
Reverse: 5′-AACCATTCCAAAAATACACACATCT 
TA-3′). Sequencing libraries were made using the NEB-
Next Multiplex Sample Kit (NEB). These primers were 
also modified for incorporation into the BisPCR2 library 
preparation protocol, as described below.
Genomic DNA isolation and sodium bisulfite conversion
Primary human islets were obtained from the Integrated 
Islet Distribution Program (IIDP). 10,000 islet equiva-
lents were obtained from five non-diabetic and five type 
2 diabetic donors. Genomic DNA (gDNA) was extracted 
using the Qiagen® AllPrep DNA/RNA mini kit (Cat. No. 
80204) following the manufacturer’s instructions. 500 ng 
of gDNA was treated with sodium bisulfite to convert 
unmethylated cytosines using the Qiagen® EpiTect® 
Bisulfite Kit (Cat. No. 59104). Reactions were carried out 
per the manufacturer’s protocol.
Target enrichment (PCR#1)
Bisulfite-converted gDNA was PCR amplified to enrich 
for regions of interest for DNA methylation analysis. 
Primers directed to target regions were modified with 
the following partial adapter overhangs: PCR#1 Left 
Primer Overhang: 5′-ACACTCTTTCCCTACACGA 
CGCTCTTCCGATCT-3′; PCR#1 Right Primer Over-
hang: 5′-GTGACTGGAGTTCAGACGTGTGCTCTTCC 
GATCT-3′. Primers directed to the MEG3 and INS loci 
were designed using the Qiagen® PyroMark assay Design 
software. Primers for CDKN1A, PED7B and IRS1 were 
adapted from a recent study by Dayeh and colleagues 
[18]. Primer sequences and genomic coordinates are pro-
vided in Additional file  3: Table  S1. PCR reactions were 
prepared with the Qiagen® PyroMark PCR Kit (Cat. No. 
978703) per the manufacturer’s recommendations using 
2.8 ng of bisulfite-converted gDNA template per reaction 
and the suggested optimized cycling protocol. All PCR#1 
products for individual biological samples were pooled 
based on relative band intensity when 5  μl of PCR#1 
reaction from a representative sample, non-diabetic 1, 
was analyzed on a 1.5% agarose gel. Final amounts were 
combined as follows: MEG3: 6 μl, CDKN1A: 8 μl, PED7B: 
4 μl, IRS1: 4 μl, INS: 4 μl, for a total of 26 μl per biological 
sample. Each pool of PCR products was purified with the 
Qiagen® QIAquick PCR Purification Kit (Cat. No. 28104) 
per the manufacturer’s instructions.
Sample barcoding (PCR#2)
Unique DNA sequencing barcodes were incorporated 
into each sample by a subsequent round of PCR ampli-
fication. Barcoding primers are provided in Addi-
tional file  4: Table  S2. The Qiagen® PyroMark PCR kit 
was used to amplify 1  ng of pooled PCR#1 template. 
Thermocycling conditions were modified to ensure 
consistent amplification of PCR products of differ-
ent sizes and were as follows: 95°C—15  min; 10 cycles: 
94°C—30  s, touchdown 68 to 56°C—30  s, 72°C—1  min; 
72°C—10  min. PCR products were purified with Agen-
court® AMPure® XP beads (Beckman Coulter, Cat. No. 
A63881). Sample concentrations were measured using 
the Qubit® fluorometer (Life Technologies) dsDNA high 
sensitivity assay. Fragment length was determined by 
separating 1 ng of sample on an Agilent high sensitivity 
DNA assay using the 2100 Bioanalyzer (Agilent Technol-
ogies). The molarity of the libraries was quantified using 
the KAPA library quantification assay (Kapa Biosystems, 
Cat. No. KK4873).
Next‑generation sequencing
Next-generation sequencing was carried out on the Illu-
mina MiSeq using Reagent Kit v2 following the manu-
facturer’s instructions. Briefly, a 2  nM pool of BisPCR2 
libraries and 2 nM PhiX control were each denatured for 
5 min with 0.2 N NaOH and diluted to final concentra-
tions of 6 and 8  pM, respectively. The denatured pool 
was spiked with 10% denatured PhiX control and 600 μl 
of the prepared sample was loaded into the reagent car-
tridge. The sequencing reaction was carried out with 150 
base pair paired-end sequencing. Sequences were aligned 
to an in silico bisulfite-converted human genome using 
the BS Seeker program, and any CpGs covered by the first 
sequencing read were ignored in the second sequencing 
read in paired-end sequencing [20]. The fraction of meth-
ylated cytosines was calculated as the merged frequency 
of cytosines for CpGs divided by total reads. Sequencing 
and DNA methylation analysis were carried out by the 
Next Generation Sequencing Core at the University of 
Pennsylvania (Philadelphia, PA, USA) [GEO: GSE69595].
Pyrosequencing
Pyrosequencing was performed to technically validate 
BisPCR2 at the MEG3 locus. Forward and reverse primers 
designed with Qiagen® PyroMark Assay Design software 
were used for both methods, and for pyrosequencing 
the reverse primer was biotinylated. Pyrosequencing 
primer sequences were as follows: Forward: 5′-GGGGTG 
ATAGTTTTTGGTTTATATT-3′, Reverse: 5′-CCATAA 
CCAACACCCTATAAT-3′, Sequencing: 5′-TTTTTATA 
TATTGTGTTTGAATTTA-3′. Bisulfite-converted 
genomic DNA from human islets, processed as described 
above, was amplified with the Qiagen® PyroMark PCR 
Kit (Cat. No. 978703) per the manufacturer’s proto-
col. The pyrosequencing reaction was carried out using 
Qiagen® PyroMark Gold Q96 CDT Reagents on the 
PyroMark Q96 MD (QIAGEN) according to the manu-
facturer’s instructions.
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Statistics
Data are shown as average ± SEM (n = 5). Average per-
cent CpG methylation was compared by two-tailed t 
tests, and significance was defined as p < 0.05.
Abbreviations
NGS: next-generation sequencing; GWAS: genome-wide association study; 
WGBS: whole genome bisulfite sequencing; PCR: polymerase chain reaction; 
gDNA: genomic DNA; ND: non-diabetic; T2D: type 2 diabetic; SEM: standard 
error of the mean.
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der of adapter sequence and unique barcodes for up to 48 samples. A 
common forward primer, “Library_Primer1,” is used in combination with 
each unique barcoding reverse primer.
Statement of ethical approval 
All animal experiments were conducted in accordance with protocols 
approved by the Institutional Animal Care and Use Committee of the Univer-
sity of Pennsylvania.
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